The barriers to early diagnosis of cardiac amyloidosis in women

This site is intended for UK healthcare professionals

Sponsorship statement:

This non-promotional video has been developed and funded by Pfizer Ltd. and is intended for UK healthcare professionals only.

The barriers to early diagnosis of cardiac amyloidosis in women

13 February 2026

In this short video, Professor Fontana discusses the barriers women face in the diagnosis of cardiac amyloidosis.

Speaker

Professor Marianna Fontana, Professor of Cardiology and Honorary Consultant Cardiologist at the National Amyloidosis Centre, University College London

For more expert-led non-promotional content on heart failure, cardiac amyloidosis and ATTR-CM, please visit the Pfizer Medical website. Clicking this link will redirect you to the Pfizer Medical website, a non-promotional website developed and funded by Pfizer Ltd. for UK healthcare professionals.

Abbreviation:
ATTR-CM: Transthyretin amyloid cardiomyopathy.

PP-UNP-GBR-14079 | February 2026